ESR1 and prostate carcinoma: Treatment of LNCaP and 22Rv1 prostate cancer cells with carnosol (20–40 μM) for 48 h led to decreased expression of AR and ER-α mRNA and protein levels, as well as dose-dependently decreased cell viability with IC50 values of 19.6 μM and 22.9 μM in LNCaP and 22Rv1 cells, respectively (Table 6) [44].